{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:42:17Z","timestamp":1791477737432,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejps.2026.107525","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:38:21Z","timestamp":1775633901000},"page":"107525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Manufacturing of PSMA-T4 radiopharmaceutical kit for 99mTc labelling as an investigational medicinal product \u2013 considerations regarding compliance with GMP"],"prefix":"10.1016","volume":"221","author":[{"given":"Barbara","family":"Janota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Radzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Sawicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Drapsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Garnuszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Kuczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Staniszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Korsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3495-0197","authenticated-orcid":false,"given":"Wioletta","family":"Wojdowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejps.2026.107525_bib0001","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/1568026619666190201100739","article-title":"Recent advances in prostate-specific membrane antigen-based radiopharmaceuticals","volume":"19","author":"Diao","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejps.2026.107525_bib0002","first-page":"81","article-title":"Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2026.107525_bib0003","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","author":"Fendler","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"10.1016\/j.ejps.2026.107525_bib0004","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. ImAging"},{"key":"10.1016\/j.ejps.2026.107525_bib0005","article-title":"PSMA inhibitor derivatives for labelling with 99mTc via HYNIC, a radiopharmaceutical kit, radiopharmaceutical preparations and their use in prostate cancer Q1 diagnostics. Eur Patent EP3721907A1","author":"Sikora","year":"2022","journal-title":"Bulletin"},{"key":"10.1016\/j.ejps.2026.107525_bib0006","first-page":"426","article-title":"PSMA inhibitor derivatives for labelling with 99mTc via HYNIC","volume":"11","author":"Sikora","year":"2022","journal-title":"US Patent"},{"issue":"21","key":"10.1016\/j.ejps.2026.107525_bib0007","doi-asserted-by":"crossref","first-page":"7216","DOI":"10.3390\/molecules27217216","article-title":"[99mTc]Tc-PSMA-T4\u2014novel SPECT tracer for metastatic PCa: from bench to clinic","volume":"27","author":"Maurin","year":"2022","journal-title":"Molecules."},{"issue":"1","key":"10.1016\/j.ejps.2026.107525_bib0008","article-title":"Biodistribution and internal radiation dosimetry of a companion diagnostic radiopharmaceutical, [68Ga]PSMA-11, in subcutaneous prostate cancer xenograft model mice","volume":"11","author":"Su","year":"2021","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.ejps.2026.107525_bib0009","first-page":"1107","article-title":"Initial experience of clinical use of [99mTc]Tc-PSMA-T4 in patients with prostate cancer. A pilot study","volume":"14","author":"Cwik\u0142a","year":"2021","journal-title":"Pharm (Basel)"},{"issue":"2","key":"10.1016\/j.ejps.2026.107525_bib0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5603\/NMR.2021.0018","article-title":"SPECT-CT imaging with [99mTc]PSMA-T4 in patients with recurrent prostate cancer","volume":"24","author":"Sergieva","year":"2021","journal-title":"Nucl. Med. Rev. Cent. East. Eur."},{"key":"10.1016\/j.ejps.2026.107525_bib0011","unstructured":"European Medicines Agency. Guideline for good clinical practiceQ2 E6(R2). EMA\/CHMP\/ICH\/135\/1995. ICH E6 Good clinical Practice - Scientific Guideline, European Medicines Agency (EMA)."},{"key":"10.1016\/j.ejps.2026.107525_bib0012","unstructured":"EudraLex-The Rules Governing Medicinal Products in the European Union, vol. 4. EU Guidelines to Good Manufacturing Practice, Annex 13. Q3."},{"key":"10.1016\/j.ejps.2026.107525_bib0013","unstructured":"EMA. Guideline on the requirements to the chemical and pharmaceutical quality documentation concerningQ4 investigational medicinal products in clinical trials. EMA\/CHMP\/QWP\/545525\/2017."},{"key":"10.1016\/j.ejps.2026.107525_bib0014","unstructured":"ICH. Q2(R2): validation of analytical procedures\u2013scientific guideline. Effective from 14 06. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/ich-q2r2-validation-analytical-procedures-scient-ific-guideline."},{"key":"10.1016\/j.ejps.2026.107525_bib0015","unstructured":"Let\u2019s talk prostate cancer\u2013digital atlas. 2023. Available from: https:\/\/Q5.www.letstalkprostatecancer.com."},{"key":"10.1016\/j.ejps.2026.107525_bib0016","unstructured":"World Cancer Research Fund. Prostate cancer statistics. AvailableQ6 from: https:\/\/www.wcrf.org. Vol 1. Issue 1 2026. Manufacturing of PSMA-T4 Radiopharmaceutical Kit for 99mTc Labelling as an Investigational Medicinal Janota et al."},{"issue":"1","key":"10.1016\/j.ejps.2026.107525_bib0017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.ejps.2026.107525_bib0018","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.120.257238","article-title":"Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer","volume":"62","author":"Farolfi","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"7","key":"10.1016\/j.ejps.2026.107525_bib0019","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1007\/s00261-020-02427-4","article-title":"Positron emission tomography (PET) radiotracers for prostate cancer imaging","volume":"45","author":"Walker","year":"2020","journal-title":"Abdom. Radiol. (NY)"},{"issue":"10","key":"10.1016\/j.ejps.2026.107525_bib0020","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","article-title":"PSMA ligands for PET imaging of prostate cancer","volume":"58","author":"Schwarzenboeck","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.ejps.2026.107525_bib0021","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/ph14080713","article-title":"[68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer","volume":"14","author":"Ute","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.ejps.2026.107525_bib0022","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2967\/jnumed.121.262989","article-title":"18F-DCFPyL PET acquisition, interpretation, and reporting: suggestions after food and drug administration approval","volume":"63","author":"Song","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.ejps.2026.107525_bib0023","first-page":"315","article-title":"Detection of true positive M1 lesions by 18F-rhPSMA-7.3 PET in newly diagnosed prostate cancer: results from the phase 3 prospective LIGHTHOUSE study","volume":"41","author":"Bridget","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2026.107525_bib0024","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s00259-003-1254-6","article-title":"Clinical usefulness of 99mTc-EDDA\/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication","volume":"30","author":"P\u0142achcinska","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"10.1016\/j.ejps.2026.107525_bib0025","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3390\/pharmaceutics15030885","article-title":"Development of the 99mTc-labelled SST2 antagonist TECANT-1 for a first-in-man multicentre clinical study","volume":"15","author":"Novak","year":"2023","journal-title":"Pharmaceutics"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T11:51:08Z","timestamp":1779709868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"alternative-id":["S0928098726000990"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107525","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Manufacturing of PSMA-T4 radiopharmaceutical kit for 99mTc labelling as an investigational medicinal product \u2013 considerations regarding compliance with GMP","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107525"}}